Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AZD1222 and rAd26-S Heterologous Prime-Boost
NCT04684446Phase 2Completed
- Sponsor
- R-Pharm
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Viral Vector Vaccines, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1 nCoV-19, rAd26 in coronavirus disease 2019 (COVID-19), sponsored by R-Pharm. Started Sep 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19rAd26
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04684446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684446.